Physician profile
Patrick Houghton
NPI 1922531383
$3,788.74
in general payments reported to CMS, 2019-2025
30 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $24.73 · 2021: $180 · 2022: $392 · 2023: $1,395 · 2024: $356 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220 · Travel and Lodging: $744 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.49 |
| Travel and Lodging | $743.61 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $961.11 | 2023 | Da Vinci Surgical System |
| Cook Medical LLC | $776.97 | 2019-2022 | |
| Boston Scientific Corporation | $213.04 | 2019 | |
| Astellas Pharma US INC | $185.61 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $159.09 | 2019 | |
| Olympus America INC. | $145.88 | 2019-2024 | Itind System, Bovie |
| Laborie Medical Technologies Corp. | $145.20 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Karl Storz Endoscopy-America | $141.43 | 2019 | |
| Ferring Pharmaceuticals INC. | $129.39 | 2023 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $115.25 | 2022-2025 | |
| Janssen Biotech, INC. | $94.28 | 2022-2025 | Erleada, Akeega, Balversa |
| Procept Biorobotics Corporation | $91.26 | 2022 | |
| Dendreon Pharmaceuticals LLC | $86.67 | 2022-2024 | Provenge |
| Axonics, INC. | $77.24 | 2023-2024 | Bulkamid, Axonics |
| Progenics Pharmaceuticals, INC. | $58.63 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $57.53 | 2023-2024 | Orgovyx, Gemtesa |
| Pfizer INC. | $36.14 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Verity Pharmaceuticals INC. | $33.88 | 2023-2024 | Trelstar |
| Novartis Pharmaceuticals Corporation | $31.19 | 2023 | |
| Merck Sharp & Dohme LLC | $29.69 | 2023-2024 | Lynparza, Keytruda |
| Urovant Sciences INC | $26.79 | 2022 | |
| Calyxo, INC. | $26.31 | 2025 | Cvac Aspiration System |
| Vertex Pharmaceuticals Incorporated | $24.27 | 2025 | |
| Angiodynamics, INC. | $22.92 | 2025 | Nanoknife |
| Alnylam Pharmaceuticals INC. | $21.21 | 2024 | Oxlumo |
| Abc Home Medical Supply, INC. | $18.69 | 2025 | |
| Coloplast Corp | $15.84 | 2023 | Porges Coloplast |
| Telix Pharmaceuticals | $15.29 | 2025 | Illuccix |
| Tolmar Pharmaceuticals, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Houghton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.